mghakemi | MUI Profession Profile

ProfileSearch

Provider
	Mazdak Ganjalikhani hakemi , PhD Associate Professor Google Scholar Orcid Isid Linkedin Scopus Phone: +98-31-37929082 Email: mghakemi@med.mui.ac.ir Date of birth : 00 CV: CV-Sep 2021-HFA.pdf (353.75 KB) Personal information Research Teaching School : School of Medicine Department : Department of Immunology Research Center : work address : Hezar Jarib St. PC: 8174673461 Education : Ph.D. Immunology, Grade: 18.82/20, Isfahan University of Medical Sciences, Isfahan, Iran 2011 M.Sc. Immunology, Grade: 18.23/20, Tehran University of Medical Sciences, Tehran, Iran 2002 B.Sc. Laboratory sciences, Grade: 18.08/20, Iran University of Medical Sciences, Tehran, Iran 1999 Relevant Work Experience : Working as an academic staff since 2011, I have got valuable experiences in the field of immunology, as well as excellent skills and understanding of cellular and molecular biology. As a “university lecturer”, I have been involved in instruction of different aspects of Immunology, both theoretical and practical courses, for “undergraduate” as well as “postgraduate” students of different disciplines in medical sciences for 10 years. I have also been involved in e-learning and virtual education for four years and such an activity has been accelerated since Corona viruse outbreak. As a researcher, I have supervised and conducted about 60 projects and dissertations during my career. Collaborating with national and international scientists, I have written and published 118 Scientific Papers in international peer reviewed scientific journals as well as 18 scientific books in the field of immunology. Two national patents and one gene registration are other academic achievements of mine. My main field of research is “molecular immunology” for understanding immunopathogenesis of diseases as well as looking for improved immunotherapeutic approaches. Based on my previuos experiences in the industry of biotechnology in a renowned company, I also have successfully completed some innovative researches such as: Production of a camel antibody (nanobody), Single-chain variable region (SCFV), IFNβ-ScFv fusion protein against collagen II, and CAR-NK cell against CD25. Constructing of gene-modified adipose derived stem cells over-expressing immunomodulatory cytokines and evaluating their potential “therapeutic effects” on EAE mice. Designing of a rapid detection kit for the diagnosis of COVID-19 virus, based on isothermal PCR. Professional Memberships & Qualification : 1st rank in Ph.D.program in Immunology. Isfahan University of Medical Sciences, Faculty of Medicine, Iran, Jul 2011. 3.5 years scholarship winner for PhD program. Isfahan University of Medical Sciences, Iran, Mar 2008. Winner of the bestbook of 2004 for the translation of “Cellular & Molecular Immunology". Iran, 2004. Extra Curricular Activities/ Interest(personal url) : Grants & Awards : Patents : Presentations & Poster Sessions : Construction of a chimeric antigen receptor (CAR) expressing natural killer (NK) cell against CD25. (2016-2020). Evaluation of the therapeutic potential of transplantation of human Adipose Derived Stem cells over-expressing LIF and IFNb for treating the EAE mice. (2018-2020). Assessment of The Impact of Tim-3/Galectin-9 Interaction on Markers of Glucose and Lipid Metabolism in Acute Myeloid Leukemia (AML) Cell Lines. (2021, …). The Effect of PD-L1 Signalling Pathway on Fatty Acid Metabolism and Pentose Phosphate Pathway as Indicators of Survival and Proliferation of AML Cell lines. (2021, …). Research Experience : Rezaei M, Tan J, Zeng C, Li Y, Ganjalikhani-Hakemi M. TIM-3 and Leukemia; The Immune Response and Beyond Frontiers in Oncology. 2021; 11:753677. DOI: 10.3389/fonc.2021.753677. Bidram M, Zhao Y, Shebardina NG, Baldin AV, Bazhin AV, Ganjalikhany MR, ..., Ganjalikhani-Hakemi M. mRNA-based cancer vaccine: A therapeutic strategy for the treatment of melanoma patients. Vaccines. 2021; 9: 1060-1093. DOI: 10.3390/vaccines9101060 Dehbashi M, Hojati Z, Motovali-bashi M, Ganjalikhany MR, Cho WC, Shimosaka A, …, Ganjalikhani-Hakemi M. A novel CAR expressing NK cell targeting CD25 with the prospect of overcoming immune escape mechanism in cancers. Frontiers in Oncology. 2021; DOI: 10.3389/fonc.2021.649710. Aria H, Ghaedrahmati F, Ganjalikhani-Hakemi M. Cutting Edge: Metabolic Immune Reprogramming, Reactive Oxygen Species and Cancer. Journal of Cellular Physiology. 2021; DOI: 10.1002/jcp.30303. Ganjalikhani Hakemi M, Jafarinia M, Azizi M, Rezaeepoor M, Isayev O, Bazhin AV. The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy? Frontiers in Oncology. 2020; DOI: 10.3389/fonc.2020.601661. Jafarinia M, Alsahebfosoul F, Salehi H, Eskandari N, Azimzadeh M, Mahmoodi M, …, Ganjalikhani-Hakemi M. Therapeutic effects of extracellular vesicles from human adipose-derived mesenchymal stem cells on chronic experimental autoimmune encephalomyelitis. Journal of Cellular Physiology. Apr 2020, DOI: 10.1002/jcp.29721 Ashja-Arvan M, Dehbashi M, Eslami A, Salehi H, Yoosefi M, Ganjalikhani-Hakemi M. Impact of IFN-β and LIF overexpression in human adipose-derived stem cells (hADSCs) properties. Journal of Cellular Physiology. Apr 2020, DOI: 10.1002/jcp.29717. Azimzadeh M, Mahmoodi M, Kazemi M, Ganjalikhani hakemi M, Jafarinia M, Eslami A, et al. The immunoregulatory and neuroprotective effects of human adipose derived stem cells overexpressing IL-11 and IL-13 in the experimental autoimmune encephalomyelitis mice. International Immunopharmacology. 2020;10.1016/j.intimp.2020.106808. Nekooie-Marnany N, Deswarte C, Ostadi V, Bagherpour B, Taleby E, Ganjalikhani Hakemi M et al. Impaired IL-12- and IL-23-Mediated Immunity Due to IL-12Rβ1 Deficiency in Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease. Journal of Clinical Immunology. 2018; DOI: 10.1007/s10875-018-0548-1. Yazdani R, Ganjalikhani-Hakemi M, Esmaeili M, Abolhassani H, Vaeli S, Rezaei A, et al. Impaired Akt phosphorylation in B-cells of patients with common variable immunodeficiency. Clinical Immunology. 2017; 175:124-32. Research Interests : 1-Genetic and functional analysis of Th17 cells in patients with susceptibility to recurrent candidiasis. Collaborating centers: Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Necker Medical School, INSERM U1163and University Paris Descartes, Sorbonne Paris Cité, Imagine Institute, Paris, France, EU. St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, NY, USA. Howard Hughes Medical Institute, NY, USA. Pediatric Hematology-Immunology Unit, Assistance Publique-Hôpitaux de Paris AP-HP, Necker Hospital for Sick Children, Paris, France, EU. 2-Evaluation of IL-12- and IL-23-Mediated Immunity in Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease. Collaborating centers: Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Imagine Institute, Necker Hospital for Sick Children, Paris, EU, France 3 Paris Descartes University, Paris, EU, France Center for the Study of Primary Immunodeficiencies, Assistance Publique-Hôpitaux de Paris AP-HP, Necker Hospital for Sick Children, Paris, EU, France Department of Pediatrics, Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-Universität München, Munich, EU, Germany St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA Howard Hughes Medical Institute, New York, NY, US 3-The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy? Collaborating centers: Department of Cytology, Embryology and Histology, Azerbaijan Medical University, Baku, Azerbaijan Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians University of Munich, Munich, Germany 4- Computational study for suppression of CD25/IL-2interaction. Collaborating centers: School of Oncology, Peking University, Beijing, China Department of Clinical Oncology, Queen Elizabeth Hospital, HKSAR, China 5- TIM-3 and Leukemia; The Immune Response and Beyond Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China, Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China 6-mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians University of Munich, 81377 Munich, Germany Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, 117997 Moscow, Russia German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany Department of Biotechnology, Sirius University of Science and Technology, 1 Olympic Ave, 354340 Sochi, Russia Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7X, UK Teaching Experience : Teaching Interests :

Provider

Mazdak Ganjalikhani hakemi , PhD

Associate Professor

Phone: +98-31-37929082
Email: mghakemi@med.mui.ac.ir
Date of birth : 00
CV: CV-Sep 2021-HFA.pdf (353.75 KB)

School :

School of Medicine

Department :

Department of Immunology

Research Center :

work address :

Hezar Jarib St. PC: 8174673461

Education :

Ph.D. Immunology, Grade: 18.82/20, Isfahan University of Medical Sciences, Isfahan, Iran 2011 M.Sc. Immunology, Grade: 18.23/20, Tehran University of Medical Sciences, Tehran, Iran 2002 B.Sc. Laboratory sciences, Grade: 18.08/20, Iran University of Medical Sciences, Tehran, Iran 1999

Relevant Work Experience :

Working as an academic staff since 2011, I have got valuable experiences in the field of immunology, as well as excellent skills and understanding of cellular and molecular biology. As a “university lecturer”, I have been involved in instruction of different aspects of Immunology, both theoretical and practical courses, for “undergraduate” as well as “postgraduate” students of different disciplines in medical sciences for 10 years. I have also been involved in e-learning and virtual education for four years and such an activity has been accelerated since Corona viruse outbreak. As a researcher, I have supervised and conducted about 60 projects and dissertations during my career. Collaborating with national and international scientists, I have written and published 118 Scientific Papers in international peer reviewed scientific journals as well as 18 scientific books in the field of immunology. Two national patents and one gene registration are other academic achievements of mine. My main field of research is “molecular immunology” for understanding immunopathogenesis of diseases as well as looking for improved immunotherapeutic approaches. Based on my previuos experiences in the industry of biotechnology in a renowned company, I also have successfully completed some innovative researches such as: Production of a camel antibody (nanobody), Single-chain variable region (SCFV), IFNβ-ScFv fusion protein against collagen II, and CAR-NK cell against CD25. Constructing of gene-modified adipose derived stem cells over-expressing immunomodulatory cytokines and evaluating their potential “therapeutic effects” on EAE mice. Designing of a rapid detection kit for the diagnosis of COVID-19 virus, based on isothermal PCR.

Professional Memberships & Qualification :

1st rank in Ph.D.program in Immunology. Isfahan University of Medical Sciences, Faculty of Medicine, Iran, Jul 2011. 3.5 years scholarship winner for PhD program. Isfahan University of Medical Sciences, Iran, Mar 2008. Winner of the bestbook of 2004 for the translation of “Cellular & Molecular Immunology". Iran, 2004.

Extra Curricular Activities/ Interest(personal url) :

Grants & Awards :

Patents :

Presentations & Poster Sessions :

Construction of a chimeric antigen receptor (CAR) expressing natural killer (NK) cell against CD25. (2016-2020). Evaluation of the therapeutic potential of transplantation of human Adipose Derived Stem cells over-expressing LIF and IFNb for treating the EAE mice. (2018-2020). Assessment of The Impact of Tim-3/Galectin-9 Interaction on Markers of Glucose and Lipid Metabolism in Acute Myeloid Leukemia (AML) Cell Lines. (2021, …). The Effect of PD-L1 Signalling Pathway on Fatty Acid Metabolism and Pentose Phosphate Pathway as Indicators of Survival and Proliferation of AML Cell lines. (2021, …).

Research Experience :

Rezaei M, Tan J, Zeng C, Li Y, Ganjalikhani-Hakemi M. TIM-3 and Leukemia; The Immune Response and Beyond Frontiers in Oncology. 2021; 11:753677. DOI: 10.3389/fonc.2021.753677. Bidram M, Zhao Y, Shebardina NG, Baldin AV, Bazhin AV, Ganjalikhany MR, ..., Ganjalikhani-Hakemi M. mRNA-based cancer vaccine: A therapeutic strategy for the treatment of melanoma patients. Vaccines. 2021; 9: 1060-1093. DOI: 10.3390/vaccines9101060 Dehbashi M, Hojati Z, Motovali-bashi M, Ganjalikhany MR, Cho WC, Shimosaka A, …, Ganjalikhani-Hakemi M. A novel CAR expressing NK cell targeting CD25 with the prospect of overcoming immune escape mechanism in cancers. Frontiers in Oncology. 2021; DOI: 10.3389/fonc.2021.649710. Aria H, Ghaedrahmati F, Ganjalikhani-Hakemi M. Cutting Edge: Metabolic Immune Reprogramming, Reactive Oxygen Species and Cancer. Journal of Cellular Physiology. 2021; DOI: 10.1002/jcp.30303. Ganjalikhani Hakemi M, Jafarinia M, Azizi M, Rezaeepoor M, Isayev O, Bazhin AV. The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy? Frontiers in Oncology. 2020; DOI: 10.3389/fonc.2020.601661. Jafarinia M, Alsahebfosoul F, Salehi H, Eskandari N, Azimzadeh M, Mahmoodi M, …, Ganjalikhani-Hakemi M. Therapeutic effects of extracellular vesicles from human adipose-derived mesenchymal stem cells on chronic experimental autoimmune encephalomyelitis. Journal of Cellular Physiology. Apr 2020, DOI: 10.1002/jcp.29721 Ashja-Arvan M, Dehbashi M, Eslami A, Salehi H, Yoosefi M, Ganjalikhani-Hakemi M. Impact of IFN-β and LIF overexpression in human adipose-derived stem cells (hADSCs) properties. Journal of Cellular Physiology. Apr 2020, DOI: 10.1002/jcp.29717. Azimzadeh M, Mahmoodi M, Kazemi M, Ganjalikhani hakemi M, Jafarinia M, Eslami A, et al. The immunoregulatory and neuroprotective effects of human adipose derived stem cells overexpressing IL-11 and IL-13 in the experimental autoimmune encephalomyelitis mice. International Immunopharmacology. 2020;10.1016/j.intimp.2020.106808. Nekooie-Marnany N, Deswarte C, Ostadi V, Bagherpour B, Taleby E, Ganjalikhani Hakemi M et al. Impaired IL-12- and IL-23-Mediated Immunity Due to IL-12Rβ1 Deficiency in Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease. Journal of Clinical Immunology. 2018; DOI: 10.1007/s10875-018-0548-1. Yazdani R, Ganjalikhani-Hakemi M, Esmaeili M, Abolhassani H, Vaeli S, Rezaei A, et al. Impaired Akt phosphorylation in B-cells of patients with common variable immunodeficiency. Clinical Immunology. 2017; 175:124-32.

Research Interests :

1-Genetic and functional analysis of Th17 cells in patients with susceptibility to recurrent candidiasis. Collaborating centers: Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Necker Medical School, INSERM U1163and University Paris Descartes, Sorbonne Paris Cité, Imagine Institute, Paris, France, EU. St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, NY, USA. Howard Hughes Medical Institute, NY, USA. Pediatric Hematology-Immunology Unit, Assistance Publique-Hôpitaux de Paris AP-HP, Necker Hospital for Sick Children, Paris, France, EU. 2-Evaluation of IL-12- and IL-23-Mediated Immunity in Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease. Collaborating centers: Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Imagine Institute, Necker Hospital for Sick Children, Paris, EU, France 3 Paris Descartes University, Paris, EU, France Center for the Study of Primary Immunodeficiencies, Assistance Publique-Hôpitaux de Paris AP-HP, Necker Hospital for Sick Children, Paris, EU, France Department of Pediatrics, Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-Universität München, Munich, EU, Germany St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA Howard Hughes Medical Institute, New York, NY, US 3-The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy? Collaborating centers: Department of Cytology, Embryology and Histology, Azerbaijan Medical University, Baku, Azerbaijan Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians University of Munich, Munich, Germany 4- Computational study for suppression of CD25/IL-2interaction. Collaborating centers: School of Oncology, Peking University, Beijing, China Department of Clinical Oncology, Queen Elizabeth Hospital, HKSAR, China 5- TIM-3 and Leukemia; The Immune Response and Beyond Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China, Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China 6-mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians University of Munich, 81377 Munich, Germany Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, 117997 Moscow, Russia German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany Department of Biotechnology, Sirius University of Science and Technology, 1 Olympic Ave, 354340 Sochi, Russia Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7X, UK